|  |
| --- |
| [**SPS home**](http://www.sps.nhs.uk) **|** [**Contact**](mailto:nwmedinfo@nhs.net?subject=New%20Medicines%20Newsletter) |

|  |  |
| --- | --- |
| **New product information** | |
|  | |
| ***Launched in the UK (or licence change for existing products)*** | |
| Alirocumab (*Praluent*)  75mg, 150mg and 300mg prefilled pens | Use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, and in paediatric patients aged ≥8 years with heterozygous familial hypercholesterolaemia (HeFH) as an adjunct to diet, in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated [licence change from use only in adults] |
| Azathioprine (*Jayempi*)  10mg in 1mL oral suspension | Use in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants; use as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response; use in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in specified diseases; use for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice; use in adults in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine; use for the treatment of generalised myasthenia gravis [new formulation]  *Note: we have shortened the wording of this indication to save space – see* [*SmPC*](https://www.medicines.org.uk/emc/product/12745) *for full details* |
| Cemiplimab (*Libtayo*)  350mg in 7mL vial | Use in combination with platinum‐based chemotherapy for the first‐line treatment of adults with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC [new indication] |
| Clopidogrel (*Plavix*)  75mg and 300mg tablets | Use in adults suffering from acute coronary syndrome with ST segment elevation acute myocardial infarction, in combination with acetylsalicyclic acid in patients undergoing percutaneous coronary intervention (including patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy [new indication] |
| Dolutegravir + abacavir + lamivudine (*Triumeq*) 5mg/60mg/30mg dispersible tablet | Treatment of human immunodeficiency virus infected children weighing 14kg to <25kg [new dispersible tablet formulation for a younger age group] |
| Drospirenone (*Slynd*)  4mg tablet | Contraception |
| Eculizumab biosimilar (*Bekemv*) 300mg in 30mL vial | Use in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria. Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history. |
| Eculizumab biosimilar (*Bekemv*) 300mg in 30mL vial | Use in adults and children for the treatment of atypical haemolytic uraemic syndrome [new indication] |
|  | |
|  | |

|  |  |
| --- | --- |
| **New product information** | |
|  | |
| ***Launched in the UK (or licence change for existing products)* (continued)** | |
| Eculizumab biosimilar (*Epysqli*) 300mg in 30mL vial | Use in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria. Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history. |
| Eculizumab (*Soliris*)  300mg vial | Treatment of refractory generalised myasthenia gravis in patients aged ≥6 years who are anti-acetylcholine receptor antibody-positive [licence change from use only in adults] |
| Elranatamab (*Elrexfio*)  44mg in 1.1mL and 76mg in 1.9mL vials | Monotherapy for the treatment of adults with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy |
| Evinacumab (*Evkeeza*) 345mg in 2.3mL vial | Use as an adjunct to diet and other low-density lipoprotein-cholesterol lowering therapies for the treatment of adult and adolescents aged ≥12 years with homozygous familial hypercholesterolaemia |
| Human normal immunoglobulin (*Cuvitru*)  1g in 5mL, 2 in 10mL, 4g in 20mL, 8g in 40mL and 10g in 50mL vials | Replacement therapy in adults, and children and adolescents (0-18 years) in primary immunodeficiency syndromes with impaired antibody production and secondary immunodeficiencies in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure or serum IgG level of <4g/l [licence change with addition of ´secondary immunodeficiencies in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure or serum IgG level of <4g/l’ and removal of ´hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed or are contra-indicated, hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma patients, and hypogammaglobulinaemia in patients pre- and post-allogeneic haematopoietic stem cell transplantation´] |
| Ivacaftor (*Kalydeco*)  59.5mg and 75mg granules in sachets | Use as monotherapy for the treatment of infants aged ≥1 month, toddlers and children weighing 3kg to <25kg with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (class III) mutations in the CF transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. Also use in a combination regimen with ivacaftor/tezacaftor/ elexacaftor for the treatment of CF in paediatric patients aged 2 to <6 years who have at least one F508del mutation in the CFTR gene [new strength formulations] |
| Loncastuximab tesirine  (*Zynlonta*) 10mg vial | Monotherapy for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after ≥2 lines of systemic therapy |
| l-tryptophan (*Optimax*) 500mg capsule | Treatment of adults with treatment-resistant depression after trials of standard antidepressant drug treatments and as an adjunct to other anti-depressant medication |
| Momelotinib (*Omjjara*)  100mg, 150mg and 200mg tablets | Treatment of disease-related splenomegaly or symptoms in adults with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase inhibitor naïve or have been treated with ruxolitinib |
| Nivolumab + relatlimab (*Opdualag*)  240mg/80mg in 20mL vial | First-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents aged ≥12 years |
| Oritavancin (*Tenkasi*)  400mg vial | Treatment of acute bacterial skin and skin structure infections in adults and paediatric patients aged ≥3 months [licence change from use only in adults] |
| Pembrolizumab (*Keytruda*)  100mg in 4mL vial | Use in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥1 [new indication] |
| Pembrolizumab (*Keytruda*)  100mg in 4mL vial | Use in combination with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults [new indication] |
|  | |
|  | |

|  |  |
| --- | --- |
| **New product information** | |
|  | |
| ***Launched in the UK (or licence change for existing products)* (continued)** | |
| Respiratory syncytial virus vaccine (*Abrysvo*)  Single-dose vial | Passive protection against lower respiratory tract disease caused by respiratory syncytial virus in infants from birth through 6 months of age following maternal immunisation during pregnancy and active immunisation of individuals aged ≥60 years for the prevention of lower respiratory tract disease caused by respiratory syncytial virus |
| Satralizumab (*Enspryng*)  120mg in 1mL prefilled syringe | Use as a monotherapy or in combination with immunosuppressive therapy for the treatment of neuromyelitis optica spectrum disorders in adults and adolescents aged ≥12 years who are anti-aquaporin-4 IgG seropositive |
| Tezepelumab (*Tezspire*)  210mg in 1.91mL prefilled pen | Use as an add-on maintenance treatment in adults and adolescents aged ≥12 years with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment [new prefilled pen formulation] |
| Tirzepatide  (*Mounjaro KwikPen*)  2.5mg/dose, 5mg/dose, 7.5mg/dose, 10mg/dose, 12.5mg/dose and 15mg/dose prefilled pen | Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, and in addition to other medicinal products for the treatment of diabetes. Also for weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥30kg/m2 (obesity) or ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus) [new multi-dose pen formulation] |
| Tocilizumab biosimilar (*Tyenne*)  162mg in 0.9mL prefilled pen | Treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with methotrexate (MTX), treatment of moderate to severe active RA in adults who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs or tumour necrosis factor antagonists, treatment of active systemic juvenile idiopathic arthritis in patients aged ≥12 years who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids, treatment of juvenile idiopathic polyarthritis in patients aged ≥12 years who have responded inadequately to previous therapy with MTX, and treatment of giant cell arteritis in adults  *Note: we have shortened the wording of this indication to save space – see* [*SmPC*](https://www.medicines.org.uk/emc/product/15242/smpc) *for full details* |
| Tocilizumab biosimilar (*Tyenne*)  162mg in 0.9mL prefilled syringe | Treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with methotrexate (MTX), treatment of moderate to severe active RA in adults who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs or tumour necrosis factor antagonists, treatment of active systemic juvenile idiopathic arthritis in patients aged ≥1 year who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids, treatment of juvenile idiopathic polyarthritis in patients aged ≥2 years who have responded inadequately to previous therapy with MTX, and treatment of giant cell arteritis in adults  *Note: we have shortened the wording of this indication to save space – see* [*SmPC*](https://www.medicines.org.uk/emc/product/15243/smpc) *for full details* |
| Tocilizumab biosimilar (*Tyenne*)  80mg in 4mL, 200mg in 10mL and 400mg in 20mL vials | Treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with methotrexate (MTX), treatment of moderate to severe active RA in adults who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs or tumour necrosis factor antagonists, treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation, treatment of active systemic juvenile idiopathic arthritis in patients aged ≥2 years who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids, treatment of juvenile idiopathic polyarthritis in patients aged ≥2 years who have responded inadequately to previous therapy with MTX, and treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome in adults and paediatric patients aged ≥2 years  *Note: we have shortened the wording of this indication to save space – see* [*SmPC*](https://www.medicines.org.uk/emc/product/15244/smpc) *for full details* |
|  | |
|  | |

|  |  |
| --- | --- |
| **New product information** | |
|  | |
| ***Launched in the UK (or licence change for existing products)* (continued)** | |
| Tralokinumab (*Adtralza*)  300mg in 2mL prefilled pen | Treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients aged ≥12 years who are candidates for systemic therapy [new formulation] |
| Tremelimumab (*Imjudo*)  25mg in 1.25mL vial and 300mg in 15mL vial | Use in combination with durvalumab for the first-line treatment of adults with advanced or unresectable hepatocellular carcinoma |
| Zanubrutinib (*Brukinsa*) 80mg capsule | Use in combination with obinutuzumab for the treatment of adults with refractory or relapsed follicular lymphoma who have received at least two prior systemic therapies [new indication] |
|  | |
|  | |

|  |  |
| --- | --- |
| **Regulatory changes in the UK or EU** | |
|  | |
| ***Approved in the UK*** | |
| Crisantaspase (*Enrylaze*) 10mg in 0.5mL vial | Use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia and lymphoblastic lymphoma in adult and paediatric patients aged ≥1 month who developed hypersensitivity or silent inactivation to *E. coli*-derived asparaginase |
| Denosumab (*Xgeva*)  120mg in 1.7mL prefilled syringe | Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone, and treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity  [new prefilled syringe formulation] |
| Efgartigimod alfa (*Vyvgart*)  1,000mg in 5.6mL vial | Use as an add-on to standard therapy for the treatment of generalised myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive [new subcutaneous formulation] |
| Influenza vaccine (*Zoonotic influenza vaccine [H5N1]*) Single dose prefilled syringe | Active immunisation against H5 subtype of influenza A virus in adults |
| Ivermectin  3mg tablets | Treatment of gastrointestinal strongyloidiasis (anguillulosis), suspected or diagnosed microfilaraemia in patients with lymphatic filariasis due to Wuchereria bancrofti, and sarcoptic scabies in adults and children weighing ≥15kg |
| Latanoprost (*Catiolanze*) 50micrograms/mL eye drops in 0.3mL single dose containers | Reduction of elevated intraocular pressure (IOP) in adults with open angle glaucoma or ocular hypertension, and reduction of elevated IOP in children aged ≥4 years and adolescents with elevated IOP and paediatric glaucoma [new preservative-free formulation] |
| Latanaprost (*Lotacryn*)  50micrograms/mL eye drops in 2.5mL bottle | Reduction of elevated intraocular pressure (IOP) in adults (including the elderly) with open angle glaucoma and ocular hypertension, and reduction of elevated IOP in paediatric patients with elevated IOP and paediatric glaucoma [new preservative-free formulation] |
| Povidone iodine  50mg/mL eye drops in 4mL bottle | Preparation of the operating ophthalmic field (eyelids, eyelashes and cheeks) and for cleaning the eye and its surroundings in case of eye surgery [new formulation]  *Note: Detail of indication provided by company but SmPC not yet available on MHRA website to confirm* |
| Ranibizumab biosimilar (*Rimmyrah*)  2.3mg in 0.23mL vials | Treatment of neovascular (wet) age-related macular degeneration, visual impairment due to diabetic macular oedema, proliferative diabetic retinopathy, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) and visual impairment due to choroidal neovascularisation |
| Trametinib (*Spexotras*)  0.05mg in 1mL powder for oral solution | Use in combination with dabrafenib for treatment of paediatric patients aged ≥1 year with low-grade glioma with a BRAF V600E mutation who require systemic therapy, and use in combination with dabrafenib for treatment of paediatric patients aged ≥1 year with high-grade glioma with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment |
|  | |
|  |  |

|  |  |
| --- | --- |
| **Regulatory changes in the UK or EU** | |
|  |  |
| ***Recommended for approval in the UK or EU*** | |
| Abrocitinib (*Cibinqo*) | Treatment of moderate-to-severe atopic dermatitis in adults and adolescents aged ≥12 years who are candidates for systemic therapy [EU] [licence change from use only in adults]  *Note: Already licensed for treatment of adolescents in the UK* |
| Ciltacabtagene autoleucel (*Carvykti*) | Treatment of adults with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide [EU] [licence change from use only after three prior therapies] |
| Danicopan (*Voydeya*) | Use as an add-on to ravulizumab or eculizumab for the treatment of adults with paroxysmal nocturnal haemoglobinuria who have residual haemolytic anaemia [EU] |
| Denosumab (*Xgeva*) | Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone, and treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity [EU]  [new prefilled syringe formulation] *Note: This formulation already licensed in the UK* |
| Hydroxycarbamide (*Xromi*) | Prevention of vaso-occlusive complications of sickle cell disease in patients aged >9 months [EU] [licence change from use only in patients aged >2 years] |
| Influenza vaccine (*Celldemic*) | Active immunisation against H5N1 subtype of influenza A virus in adults and infants aged ≥6 months [EU] |
| Influenza vaccine (*Incellipan*) | Active immunisation against influenza in an officially declared pandemic [EU] |
| Ivacaftor (*Kalydeco*) | Use as monotherapy for the treatment of infants aged ≥1 month, toddlers and children weighing 3kg to <25kg with cystic fibrosis who have an R117H CFTR mutation or one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R [EU] [licence change from use only in infants aged ≥4 months weighing ≥5kg and new 13.4mg strength granules in sachet formulation] *Note: Already licensed in the UK but not yet launched* |
| Luspatercept (*Reblozyl*) | Use in adults for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes [EU] [licence change from use only in adults with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy] |
| Pembrolizumab (*Keytruda*) | Use in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, for the treatment of resectable non‑small cell lung carcinoma at high risk of recurrence in adults [EU] [new indication] |
| Retifanlimab (*Zynyz*) | Use as monotherapy for the first‑line treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma not amenable to curative surgery or radiation therapy [EU] |
| Sparsentan (*Filspari*) | Treatment of adults with primary immunoglobulin A nephropathy with a urine protein excretion >1.0g/day (or urine protein-to-creatinine ratio ≥0.75 g/g) [EU] |
| Terbinafine (*Terclara*) | Treatment of mild to moderate fungal nail infections caused by dermatophytes and/or other fungi sensitive to terbinafine in adults [EU] [new formulation] |
| Tislelizumab (*Tizveni*) | Use as monotherapy for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior platinum-based therapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab. [EU] [new formulation with new indication] |
| Tislelizumab (*Tizveni*) | Use in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of adults with squamous non-small cell lung cancer (NSCLC) who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC [EU] [new formulation with new indication] |
|  |  |
|  |  |

|  |  |
| --- | --- |
| **Regulatory changes in the UK or EU** | |
|  |  |
| ***Recommended for approval in the UK or EU* (continued)** | |
| Tislelizumab (*Tizveni*) | Use in combination with pemetrexed and platinum‑containing chemotherapy for the first-line treatment of adults with non-squamous non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations and who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC [EU] [new formulation with new indication] |
| Tofersen sodium  (*Qalsody*) | Treatment of adults with amyotrophic lateral sclerosis associated with a mutation in the superoxide dismutase 1 gene [EU] |
| Ustekinumab biosimilar (*Pyzchiva*) | Treatment of moderate to severe plaque psoriasis in adults, adolescents and children aged ≥6 years, treatment of active psoriatic arthritis in adults, treatment of adults with moderately to severely active Crohn’s disease and treatment of adults with moderately to severely active ulcerative colitis [EU] *Note: we have shortened the wording of this indication to save space* |
|  |  |
|  |  |
| ***Filed for approval in the UK or EU*** | |
| Acoramidis | Treatment of wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy [EU] |
| Alectinib (*Alecensa*) | Use as monotherapy in adults with ALK-positive non-small cell lung cancer as adjuvant treatment following tumour resection [EU] [new indication] |
| Bempedoic acid + ezetimibe (*Nustendi*) | Prevention of cardiovascular events in patients who are at high risk for cardiovascular disease, with documented statin intolerance [EU] [new indication] |
| Enfortumab vedotin (*Padcev*) | Use with pembrolizumab as a combination therapy for the first-line treatment of adults with previously untreated locally advanced or metastatic urothelial cancer [EU] [new indication, believed to include use in patients who are and are not eligible to receive cisplatin chemotherapy] |
| Linvoseltamab | Treatment of relapsed or refractory multiple myeloma in adults, fourth-line monotherapy [EU] |
| Linzagolix (*Yselty*) | Treatment of endometriosis- associated moderate to severe pain in adult women [EU] [new indication] |
| Nemolizumab | Treatment of moderate to severe atopic dermatitis in adults and adolescents [EU] |
| Nemolizumab | Treatment of moderate to severe prurigo nodularis in adults [EU] |
| Nivolumab (*Opdivo*) | Use as neoadjuvant therapy with chemotherapy for treatment of resectable stage IIA to IIIB non-small cell lung cancer in adults followed by nivolumab monotherapy as adjuvant therapy [EU] [new indication] |
| Pembrolizumab (*Keytruda*) | Use with enfortumab vedotin as a combination therapy for the first-line treatment of adults with previously untreated locally advanced or metastatic urothelial cancer [EU] [new indication, believed to include use in patients who are and are not eligible to receive cisplatin chemotherapy] |
| Pemigatinib (*Pemazyre*) | Treatment of adults with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 rearrangement [EU] [new indication] |
| Tisotumab vedotin  (*Tivdak*) | Treatment of adults with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy [EU] |
| Tocilizumab biosimilar (*Avtozma*) | Rheumatoid arthritis and other *RoActemra* indications [EU] [IV and SC formulations] |
| Vorasidenib | Adjuvant monotherapy of residual or recurrent grade 2 glioma (oligodendroglioma or astrocytoma), IDH1 or IDH2 mutation-positive, in adults and adolescents aged ≥12 years [EU] |
|  |  |
|  |  |

|  |  |  |
| --- | --- | --- |
| **Regulatory changes in the UK or EU** | | |
|  |  | |
| ***Other UK/EU developments*** | | |
| Abemaciclib (*Verzenios*) | Metastatic castration-resistant prostate cancer in adults – development discontinued  (lack of efficacy) | |
| Adrabetadex | Type C Niemann-Pick disease in adults and children – development discontinued  (lack of efficacy) | |
| Aducanumab (*Aduhelm*) | Early Alzheimer’s disease in adults – development discontinued (company decision) | |
| Agomelatine (*Valdoxan*) | Moderate to severe major depressive episodes in adolescents aged 12 to 17 years – UK and EU development discontinued (company decision) | |
| Alicaforsen | Distal ulcerative colitis – development discontinued (company failed) | |
| Alicaforsen (*Camligo*) | Chronic antibiotic refractory pouchitis in adults – development discontinued  (company failed) | |
| Crizanlizumab (*Adakveo*) | Prevention of vaso-occlusive crises in patients aged 6 months to 15 years with sickle cell disease – development discontinued (company decision after licence in patients aged ≥16 years withdrawn) | |
| Domvanalimab | Advanced PD-L1-positive non-small cell lung cancer in adults, first-line with zimberelimab – development discontinued (company decision) | |
| Durvalumab (*Imfinzi*) | Locally advanced, unresectable non-small cell lung cancer in adults, with chemoradiation therapy – development discontinued (lack of efficacy and safety concern) | |
| Labafenogene marselecobac | Phenylketonuria in adults – development discontinued (lack of efficacy) | |
| Magrolimab | Acute myeloid leukaemia in adults unsuitable for intensive chemotherapy, first-line with azacitidine and venetoclax – development discontinued (safety concern) | |
| Parsaclisib | Primary or secondary myelofibrosis in adults – development discontinued (lack of efficacy) | |
| Patisiran (*Onpattro*) | Transthyretin amyloidosis with cardiomyopathy in adults – development discontinued  (company decision) | |
| Sacituzumab govitecan  (*Trodelvy*) | Metastatic non-small cell lung cancer in adults, second- or third-line – development discontinued (lack of efficacy) | |
| Sirolimus (*QTORIN*) | Pachyonychia congenita in adults – development discontinued (lack of efficacy) | |
| Sodium thiosulfate | Treatment of calciphylaxis-associated pain in chronic haemodialysis patients – development discontinued (company decision) | |
| TAK531 | Mucopolysaccharidosis II (Hunter syndrome) in adults – development discontinued  (company decision) | |
| Zandelisib | Relapsed or refractory CD20-positive marginal zone lymphoma or follicular lymphoma in adults – development discontinued (company decision) | |
| Zimberelimab | Advanced PD-L1-positive non-small cell lung cancer in adults, first-line with domvanalimab – development discontinued (company decision) | |
|  |  | |
|  | |  |